Kairos Pharma, Ltd.(股票代码:KAPA.A)近日宣布了其药物ENV-105在晚期前列腺癌二期临床试验中取得的积极安全性数据。试验结果显示,ENV-105与激素治疗联合使用时耐受性良好。值得注意的是,未报告任何剂量限制毒性或意外不良事件。公司预计,中期疗效数据将于2025年9月正式发布。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.